Atara Biotherapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.88next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly8.4MTarget: Sufficient to fund operations into mid-2027
Quarterly Net Cash Used in Operating Activities Quarterly3.1MTarget: Minimize cash burn through ongoing cost-reduction initiatives
Quarterly Commercialization Revenue Quarterly516KTarget: Increase via royalties and milestone achievements
Watch Items
- Tabelecleucel (tab-cel) BLA Resubmission Plan and Regulatory UpdateTrigger: Regulatory update expected in Q3 2026Action: Monitor joint announcements from Pierre Fabre Pharmaceuticals and Atara regarding the FDA resubmission timeline and updated ALLELE study dataset.
- FDA Decision on Tabelecleucel (tab-cel) BLATrigger: Potential approval triggering a $31 million milestone paymentAction: Track FDA review progress and potential PDUFA target action date following resubmission.
- Going Concern Status and Capital Raising ActivitiesTrigger: Substantial doubt about going concern expressed in Q1 2026 filingAction: Evaluate ATM (at-the-market) program utilization, strategic transactions, or alternative financing to extend cash runway beyond mid-2027.
Research as of 19 Jun 2026